Brett Cain

Brett graduated from the University of Hawai’i at Mānoa in the Spring of 2019 with a BS in Chemistry and a BA in Microbiology. As an undergraduate he worked with Dr. Marcus Tius in the synthesis of pharmaceutical targets to selectively inhibit STAT3 — a protein implicated in many cancers. Additionally, he worked with Dr. Jon-Paul Bingham to study the impact of different configurations in alpha-conotoxins from Conus virgo in the development of anthelmintic drugs. Brett joined the Hergenrother lab in the Fall of 2019 and is currently working to synthesize novel broad-spectrum antibacterial compounds.